Stifel Nicolaus assumed coverage on shares of Cerus (NASDAQ:CERS) in a report published on Tuesday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $7.00 price target on the biotechnology company’s stock.
Other equities research analysts have also issued reports about the company. Zacks Investment Research upgraded Cerus from a sell rating to a hold rating in a research note on Tuesday, August 20th. ValuEngine upgraded Cerus from a hold rating to a buy rating in a research note on Tuesday, July 23rd. Stephens started coverage on Cerus in a research note on Thursday, August 22nd. They set an overweight rating and a $8.00 price objective for the company. Finally, BidaskClub lowered Cerus from a buy rating to a hold rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and an average price target of $7.63.
NASDAQ CERS opened at $5.33 on Tuesday. Cerus has a twelve month low of $4.49 and a twelve month high of $7.81. The company has a quick ratio of 2.33, a current ratio of 2.67 and a debt-to-equity ratio of 0.88. The stock has a 50-day moving average of $5.45 and a 200 day moving average of $5.71.
In related news, insider William Mariner Greenman purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, June 4th. The stock was acquired at an average cost of $4.60 per share, for a total transaction of $46,000.00. Following the completion of the transaction, the insider now directly owns 638,485 shares of the company’s stock, valued at $2,937,031. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Timothy B. Anderson sold 18,795 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $5.40, for a total value of $101,493.00. Following the completion of the sale, the director now owns 177,649 shares of the company’s stock, valued at $959,304.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,903 shares of company stock valued at $234,613. 7.26% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in shares of Cerus by 12.9% during the 4th quarter. Bank of America Corp DE now owns 535,458 shares of the biotechnology company’s stock valued at $2,714,000 after acquiring an additional 61,275 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Cerus by 19.3% during the 4th quarter. Legal & General Group Plc now owns 26,148 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 4,222 shares in the last quarter. FMR LLC lifted its holdings in shares of Cerus by 52,232.7% during the 4th quarter. FMR LLC now owns 647,356 shares of the biotechnology company’s stock valued at $3,282,000 after acquiring an additional 646,119 shares in the last quarter. Virtu Financial LLC lifted its holdings in shares of Cerus by 16.6% during the 1st quarter. Virtu Financial LLC now owns 12,639 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 1,798 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Cerus during the 1st quarter valued at $134,000. Institutional investors and hedge funds own 72.83% of the company’s stock.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Featured Story: Why is momentum important to successful trading?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.